Regeneron Pharmaceuticals, Inc. (REGN) Analyst Ratings & Price Targets

Regeneron Pharmaceuticals, Inc.

REGN · Nasdaq

Analyst Consensus

Buy

21 analysts

$782

Current

$854

Low

$864

Average

$860

High

Average target implies +10.45% versus the current price.

Analyst Ratings Synthesis

The consensus rating is Buy across 21 analysts. The only supplied price-target statistic is a mean of $857; low and high targets are unavailable, so the targets cannot be shown to cluster and their spread cannot be measured. The evidence does not identify the most bullish or least bullish analyst, any named firm-level targets, or the direction of revisions during the past week. It also does not document a substantive analyst disagreement behind the target distribution. Accordingly, the actionable consensus signal is broadly positive, but the breadth of conviction, target dispersion and recent changes in expectations remain unreported.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Piper Sandler	—	Unrated Lowered price target	$854from $855	+9.2%	Jul 9, 2026	Open the report this row came from
BofA Securities	—	Unrated Raised price target to $860	$860	+9.9%	Jan 7, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

CANACCORD GENUI

CANTOR FITZGERA

DEUTSCHE BK SEC

GOLDMAN SACHS

GUGGENHEIM SEC.

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RBC CAPITAL

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

WESTPARK CAPITA

Symbol: REGN
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite , which produces optimized fully human antibodies and new classes of bispecific antibodies.

Key Issues

Bullish view

Dupixent remains a key source of strength, and higher Dupixent profits helped drive the second-quarter earnings beat. Continued demand could support growth even as older products mature.

Bearish view

The evidence confirms current strength but does not establish its durability. A slowdown in Dupixent could expose the company more directly to pressure from declining Eylea sales.

Analyst Consensus

See all

Buy

21 analysts

$782

Current

$854

Low

$864

Average

$860

High

Average target implies +10.45% versus the current price.

Earnings History

BeatMissNo estimate

Regeneron Pharmaceuticals, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers